Most seriously ill COVID-19 patients will be treated with the antiviral medication Remdesivir in America the maker of the drug has announced, as tensions

The SEMDEX decreased 576 points or 26.41% since the beginning of 2020, according to trading on a contract for difference (CFD) that tracks this benchmark index from Mauritius. Historically, the Mauritius Stock Market (SEMDEX) reached an all time high of 2308.30 in March of 2018. The Mauritius Stock Exchange Semdex Index is a major stock market index which tracks the performance of all companies listed on the Stock Exchange of Mauritius. It is a free-float, capitalization-weighted index.

Exclusive: Disappointing results revealed in draft documents published accidentally by WHO

US-run trial of Gilead coronavirus therapy demonstrates ‘significant positive effect’

Gilead’s potential coronavirus treatment stirs investor hopes but evidence on effectiveness is mixed

Biotech group’s shares have soared this year on hopes drug could be used to treat coronavirus

US-led trial shows positive results in hastening recovery time for coronavirus patients

The Game Of Thrones star, 33, looked relaxed as he got to work on set of the hotly-anticipated superhero film, and strolled through Camden, London, on Thursday.

Gilead Sciences announced Wednesday that more than half of the 397 severely ill coronavirus patients it treated with the antiviral Ebola drug Remdesivir were discharged from hospitals.

In an interview with Good Morning America on Thursday, Dr. Aneesh Mehta of Emory University Medical School - one of the institutions which took part in the study - spoke of its success.

The FDA may announce its decision allowing emergency use authorization of an antiviral remdesivir for coronavirus patients as early as Wednesday.

Remdesivir, an antiviral made by California-based Gilead Sciences, was shown to slash recovery times in a global trial of more than 1,000 patients, including Britons.

Gilead Sciences CEO Daniel O'Day wrote in an open letter obtained by Fox News that early results on his company's drug remdesivir's benefits for coronavirus patients offer 'hope' that's badly needed.

Gilead Sciences said Thursday in an earnings report that it is ramping up production of its antiviral remdesivir, and could make 'several million' 10-day treatment courses of the drug for 2021.

Gilead Sciences CEO Daniel O'Day told Stat News that his company understands its responsibility to make its antiviral drug affordable after it showed promise for treating coronavirus.

President Donald Trump announced Friday that the FDA has approved the drug remdesivir for emergency use in hospitalized coronavirus patients. 

Gilead Scienced, based in California, said it's in talks with 'several' generic drug makers across Europe and Asia, including India and Pakistan, to produce its experimental coronavirus drug remdesivir.

A report from a cost watchdog estimated that it costs $9.32 to manufacture one 10-day course of remdesivir treatment and that, if proven to save live, it could cost $4,500 per treatment.

अमेरिकी कंपनी गिलियड साइंसेज (Gilead Sciences) का दावा है कि कोरोना वायरस (COVID-19) के इलाज में Remdesivir एक कारगर दवाई साबित होगी. इस पर प्रयोग जारी हैं. आइए जानते हैं इस दवाई से जुड़ी खास जरूरी बातें.

नैटको फार्मा लिमिटेड (Natco Pharma Ltd) और लॉरस लैब्स लिमिटेड (Laurus Labs Ltd) एंटी वायर ड्रग रेमेडिसविर (Remdesivir) बनाने के लाइसेंस के लिए अमेरिकी फार्मास्युटिकल कंपनी गिलियड साइंस इंक (Gilead Sciences Inc) से बातचीत की है.

Remdesivir is authorised for the treatment of hospitalised patients with severe Covid-19 disease though the optimal duration of treatment is still being studied in ongoing clinical trials.

Remdesivir is an investigational antiviral drug that may be found effective against the virus that causes Covid-19

Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

Johannesburg, Feb 5 (PTI) Commonwealth and Asian Games gold medallist Somdev Devvarman advanced to the semi-final of the South African Open after he fought back from a set down to beat local hope Rik de Voest.

An experimental antiviral drug developed by a research-based biopharmaceutical company, Gilead Sciences showed positive results on its application, where more than half of a group of severely ill coronavirus patients improved. UPDATE: On 29 April, Gilead Sciences Inc. announced that in Phase

One of Bangladesh's largest drugmakers, Beximco Pharmaceuticals, will start production this month of the experimental antiviral drug remdesivir, which has shown promise in fighting the new coronavirus, a senior company executive said on Tuesday.

Dewey Library - HC435.3.M35 2019

University of Sydney. Post-Graduate Committee in Veterinary Science

Harish Rawat, a Congress leader has spoken out against spiritual leader Ramdev, who compared Narendra Modi to Jawaharlal Nehru."Jawaharlal Nehru was one of the founders of the Indian nation. Ramdev is a fool to compare him to Modi," says Rawat in an ...

Recent clinical trial results and the decision by the US Food and Drug Administration to issue 'Emergency Use Authorisation' for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally, Gilead said.

Browsery DVD PN199.77.P48 2015

Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.

Online Resource

Online Resource

Online Resource

Checks with industry on when can production begin here for trials

Hayden Library - PT2440.N72.E43 2014

At his yoga camps, the guru has offered no excuses while seeking votes for the BJP.

Van Emden, Joan

Mazumder, B

Gilead Sciences' antiviral is in multiple late-stage trials to treat coronavirus infections. Don't expect a home run, say infectious disease experts

Gilead's Chief Medical Officer talks about the challenges of clinical design in the time of COVID-19

Manufacturing experts weigh in on Gilead's challenge in making its potential COVID-19 treatment

Manufacturing experts weigh in on Gilead's challenge in making its potential COVID-19 treatment

Limited results from a NIAID study suggest the drug helps people with COVID-19 recover faster

Interview with Yoga guru and Patanjali founder

Rotch Library - NA680.T363 2018